Archimedic, a medical device development firm that provides technical, regulatory, and commercial services to its clients, has appointed M. Alexander Shaw, PhD, as Chief Executive Officer. In this role, Dr. Shaw will lead Archimedic in helping companies transform novel technologies into market-ready products that address technical, regulatory, usability, and commercial needs.
Dr. Shaw joins founder Eric Sugalski on Archimedic’s executive team. Mr. Sugalski has led the company since its beginning, growing it into a leader in medical device development services. “Dr. Shaw’s medical product development expertise combined with his experience in successfully leading and growing a life-science consulting business makes him a perfect fit for helping Archimedic achieve its next phase of growth,” said Mr. Sugalski.
Mr. Sugalski will assume the role of Chief Technology Officer. In this role, Mr. Sugalski will leverage his extensive background in engineering, regulatory affairs, and commercial strategy to help clients advance their technologies into market-focused, derisked solutions. “I am excited to be stepping into this hands-on role working directly with our talented team and clients to advance new medical technologies,” states Mr. Sugalski.
Also Read: SpectraWAVE Secures $50M Series B for HyperVue Expansion
Bringing 15-years of leadership experience in biotech and pharma consulting, Dr. Shaw was formerly the Chief Operating Officer of Nuventra Pharma Sciences, where he co-led the company from inception into a stable, revenue generating business prior to its sale in May 2021. Regarding Archimedic, Dr. Shaw notes, “Archimedic’s demonstrated expertise in all three major segments of medical device development: design, regulatory affairs, and commercialization, provides real value to its clients, greatly improving their chances for successful commercialization of their products and bringing necessary advances to the medical field.”
Dr. Shaw earned dual Bachelor’s Degrees in Chemistry and Biology from Duke University, followed by his PhD in Biochemistry and Biophysics from Washington State University. He went on to an American Heart Association post-doctoral fellowship at the University of Pennsylvania. He co-developed Nuventra Pharma Sciences from a two-person boutique clinical pharmacology consulting shop into a 125-person full-service drug development consulting group with $22M in annual revenue.
SOURCE: Businesswire